StockNews.com Initiates Coverage on Enzo Biochem (NYSE:ENZ)

Research analysts at StockNews.com started coverage on shares of Enzo Biochem (NYSE:ENZ) in a research note issued to investors on Sunday. The brokerage set a “hold” rating on the medical research company’s stock.

Enzo Biochem Stock Performance

NYSE ENZ opened at $0.49 on Friday. The firm’s fifty day moving average is $0.55 and its two-hundred day moving average is $0.85. Enzo Biochem has a one year low of $0.41 and a one year high of $1.30.

Enzo Biochem (NYSE:ENZ) last posted its quarterly earnings data on Monday, March 17th. The medical research company reported ($0.02) earnings per share for the quarter. Enzo Biochem had a negative net margin of 75.34% and a negative return on equity of 7.96%. The firm had revenue of $7.33 million during the quarter.

Institutional Investors Weigh In On Enzo Biochem

Institutional investors have recently added to or reduced their stakes in the company. Mink Brook Asset Management LLC purchased a new position in shares of Enzo Biochem in the fourth quarter valued at $577,000. Wittenberg Investment Management Inc. boosted its position in Enzo Biochem by 60.1% in the 4th quarter. Wittenberg Investment Management Inc. now owns 187,537 shares of the medical research company’s stock valued at $134,000 after buying an additional 70,400 shares during the last quarter. Virtu Financial LLC acquired a new stake in shares of Enzo Biochem during the fourth quarter valued at about $35,000. Lepercq Multi Asset Fund purchased a new stake in shares of Enzo Biochem during the fourth quarter worth about $88,000. Finally, Geode Capital Management LLC lifted its stake in shares of Enzo Biochem by 3.3% in the third quarter. Geode Capital Management LLC now owns 368,646 shares of the medical research company’s stock worth $413,000 after acquiring an additional 11,742 shares in the last quarter. Hedge funds and other institutional investors own 36.90% of the company’s stock.

Enzo Biochem Company Profile

Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.